Ocular Therapeutix (OCUL) Tops Q3 EPS by 3c

Ocular Therapeutix (NASDAQ: OCUL) reported Q3 EPS of ($0.23), $0.03 better than the analyst estimate of ($0.26). Revenue for the quarter came in at $12.15 million versus the consensus estimate of $12.45 million.

For earnings history and earnings-related data on Ocular Therapeutix (OCUL) click here.

You May Also Be Interested In

• Wells Fargo cuts Netflix rating on engagement risk, weak slate
• Needham Reiterates Hold Rating on Envista Holdings Corp. (NVST)
• Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)